(Q58289284)

7

object named as

C Erlichman

0 references

author name string

R A Mesa

1

0 references

J K Camoriano

2

0 references

S M Geyer

3

0 references

W Wu

4

0 references

S H Kaufmann

5

0 references

C E Rivera

6

0 references

J Wright

8

0 references

A Pardanani

9

0 references

T Lasho

10

0 references

C Finke

11

0 references

C Y Li

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404816

12

0 references

publication date

21 June 2007

0 references

published in

Leukemia

0 references

volume

21

0 references

page(s)

1964-1970

0 references

issue

9

0 references

exact match

0 references

cites work

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

[Treatment with hydroxyurea of polycythemia vera in a 11 year-old child]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404816

7 January 2021